TW200305403A - Compounds that modulate PPAR activity - Google Patents

Compounds that modulate PPAR activity Download PDF

Info

Publication number
TW200305403A
TW200305403A TW092104790A TW92104790A TW200305403A TW 200305403 A TW200305403 A TW 200305403A TW 092104790 A TW092104790 A TW 092104790A TW 92104790 A TW92104790 A TW 92104790A TW 200305403 A TW200305403 A TW 200305403A
Authority
TW
Taiwan
Prior art keywords
compound
methyl
hydrogen
alkyl
acid
Prior art date
Application number
TW092104790A
Other languages
English (en)
Chinese (zh)
Inventor
Xue-Min Cheng
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Ouano Erasga Noe
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200305403A publication Critical patent/TW200305403A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26Radicals substituted by sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW092104790A 2002-03-07 2003-03-06 Compounds that modulate PPAR activity TW200305403A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
TW200305403A true TW200305403A (en) 2003-11-01

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092104790A TW200305403A (en) 2002-03-07 2003-03-06 Compounds that modulate PPAR activity

Country Status (29)

Country Link
US (1) US20030207924A1 (enExample)
EP (1) EP1482935B1 (enExample)
JP (1) JP2005528348A (enExample)
KR (1) KR20040091693A (enExample)
AP (1) AP2004003124A0 (enExample)
AR (1) AR038881A1 (enExample)
AT (1) ATE405260T1 (enExample)
AU (1) AU2003206059A1 (enExample)
BR (1) BR0308277A (enExample)
CA (1) CA2478520A1 (enExample)
CO (1) CO5601012A2 (enExample)
DE (1) DE60323060D1 (enExample)
EA (1) EA200400943A1 (enExample)
EC (1) ECSP045285A (enExample)
ES (1) ES2310650T3 (enExample)
HN (1) HN2003000090A (enExample)
IS (1) IS7377A (enExample)
MA (1) MA27181A1 (enExample)
MX (1) MXPA04007564A (enExample)
NO (1) NO20044242L (enExample)
OA (1) OA12780A (enExample)
PA (1) PA8567801A1 (enExample)
PE (1) PE20030989A1 (enExample)
PL (1) PL372969A1 (enExample)
TN (1) TNSN04168A1 (enExample)
TW (1) TW200305403A (enExample)
UY (1) UY27695A1 (enExample)
WO (1) WO2003074050A1 (enExample)
ZA (1) ZA200406068B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
BRPI0410454A (pt) * 2003-05-19 2006-06-13 Irm Llc composições e compostos imunossupressores
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
ATE486055T1 (de) 2004-05-05 2010-11-15 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
RU2392274C2 (ru) * 2005-02-25 2010-06-20 Сеул Нэшнл Юниверсити Индастри Фаундейшн Тиазольные производные в качестве лигандов ppar-дельта и способ их получения
WO2006121223A1 (en) * 2005-05-07 2006-11-16 Heon Joong Kang Process for preparing ligands of ppardelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
JP5052511B2 (ja) 2005-06-30 2012-10-17 ハイ ポイント ファーマシューティカルズ,エルエルシー Pparデルタ活性化因子としてのフェノキシ酢酸
JP5084503B2 (ja) * 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2631390C (en) 2005-12-22 2014-03-11 Per Sauerberg Phenoxy acetic acids as ppar delta activators
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
JP2010524932A (ja) 2007-04-16 2010-07-22 アムジエン・インコーポレーテツド 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 grp40 조절제
US20090163481A1 (en) * 2007-12-13 2009-06-25 Murphy Brian J Ppar-delta ligands and methods of their use
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
ES2450567T3 (es) 2008-10-15 2014-03-25 Amgen, Inc Moduladores de GPR40 espirocíclicos
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
SK21099A3 (en) * 1996-08-19 2000-05-16 Japan Tobacco Inc Propionic acid derivatives and applications thereof
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345916A1 (en) * 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
SK14922003A3 (sk) * 2001-06-07 2005-04-01 Eli Lilly And Company Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR)

Also Published As

Publication number Publication date
JP2005528348A (ja) 2005-09-22
EA200400943A1 (ru) 2005-02-24
ES2310650T3 (es) 2009-01-16
ECSP045285A (es) 2004-10-26
CO5601012A2 (es) 2006-01-31
MA27181A1 (fr) 2005-01-03
PE20030989A1 (es) 2003-11-29
MXPA04007564A (es) 2004-11-10
UY27695A1 (es) 2003-10-31
OA12780A (en) 2006-07-07
EP1482935B1 (en) 2008-08-20
NO20044242L (no) 2004-10-06
TNSN04168A1 (fr) 2007-03-12
BR0308277A (pt) 2004-12-28
CA2478520A1 (en) 2003-09-12
KR20040091693A (ko) 2004-10-28
AU2003206059A1 (en) 2003-09-16
PA8567801A1 (es) 2003-11-12
PL372969A1 (en) 2005-08-08
US20030207924A1 (en) 2003-11-06
AR038881A1 (es) 2005-02-02
EP1482935A1 (en) 2004-12-08
DE60323060D1 (de) 2008-10-02
ATE405260T1 (de) 2008-09-15
IS7377A (is) 2004-07-29
WO2003074050A1 (en) 2003-09-12
ZA200406068B (en) 2005-09-06
HN2003000090A (es) 2004-05-05
AP2004003124A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TW200305403A (en) Compounds that modulate PPAR activity
KR920002131B1 (ko) 타아졸리딘디온 유도체의 제조방법
EP2606031B1 (en) Autotaxin inhibitors and uses thereof
EP2714680B1 (en) Heterocyclic autotaxin inhibitors and uses thereof
JP2010520303A (ja) Ppar活性化合物
EA009518B1 (ru) Соединения, модулирующие активность ppar, и способы их получения
WO2002053547A1 (en) Alkanoic acid derivatives, process for their production and use thereof
JP2009507846A (ja) Ppar活性化合物
CN101466687A (zh) 过氧化物酶体增殖剂激活受体δ的激活剂
HU211138A9 (en) Therapeutic amides
JP2005529077A (ja) ペルオキシソーム増殖因子活性化受容体調節物質
WO1999046232A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
TW200400027A (en) Compounds that modulate PPAR activity
JP2007508382A (ja) Pparモジュレータとしてのフェノキシエーテル誘導体
JP6310931B2 (ja) Gpr120アゴニストとしてのチオアリール誘導体
JPWO2006059744A1 (ja) ペルオキシソーム増殖剤活性化受容体δの活性化剤
AU2004266673B2 (en) Compounds for the treatment of metabolic disorders
WO2000023442A1 (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP5295560B2 (ja) ブタン酸誘導体、その調製方法、それらを含む医薬組成物およびその治療用途
WO2006117743A1 (en) Substituted aromatic compounds as antidiabetic agents
JP3466273B2 (ja) テトラゾール誘導体、その製造法およびそれを含んでなる医薬
JP5436941B2 (ja) ラクタム化合物又はその塩及びppar活性化剤
CN107162913B (zh) 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途
US7825146B2 (en) Sulfonamide derivative having isoxazole ring
JPH0436151B2 (enExample)